Longitudinal Assessment of Plasma Syndecan-1 Predicts 60-Day Mortality in Patients with COVID-19
Journal of Clinical Medicine · 10.01.2023 · 12 (2) · 552
DOI: 10.3390/jcm12020552 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 10.01.2023. Verfasst von Quan Zhang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Pathology and Laboratory Medicine, The University of Kansas Medical Center, Kansas City, KS 66160, USA. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, NHLBI, Central South University, Changsha, China.
Abstract (Originalsprache)
Background
Endotheliopathy is a common pathologic finding in patients with acute and long COVID-19. It may be associated with disease severity and predispose patients to long-term complications. Plasma levels of a proteoglycan, syndecan-1, are found to be significantly elevated in patients with COVID-19, but its roles in assessing disease severity and predicting long-term outcome are not fully understood.
Methods
A total of 124 consecutive hospitalized patients with SARS-CoV-2 infection were prospectively enrolled and blood samples were collected on admission (T1), 3–4 days following treatment (T2), and 1–2 days prior to discharge or death (T3). Plasma levels of syndecan-1 were determined using an immunosorbent assay; various statistical analyses were performed to determine the association between plasma syndecan-1 levels and disease severity or the 60-day mortality rate.
Results
Compared with those in the healthy controls, plasma levels of syndecan-1 in patients with critical COVID-19 were significantly higher (p < 0.0001). However, there was no statistically significant difference among patients with different disease severity (p > 0.05), resulting from large individual variability. Longitudinal analysis demonstrated that while the levels fluctuated during hospitalization in all patients, plasma syndecan-1 levels were persistently elevated from baseline in critical COVID-19 patients. Cox proportional hazard regression analyses revealed that elevated plasma levels of syndecan-1 (>260 ng/mL at T1, >1018 ng/mL at T2, and >461 ng/mL at T3) were significantly associated with the 60-day mortality rate.
Conclusions
Endotheliopathy, marked by glycocalyx degradation and elevated plasma syndecan-1, occurs in nearly all hospitalized patients with SARS-CoV-2 infection; elevated plasma syndecan-1 is associated with increased mortality in COVID-19 patients.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Departments of Pathology and Laboratory Medicine, The University of Kansas Medical Center, Kansas City, KS 66160, USA.
- Institute of Reproductive and Developmental Sciences, The University of Kansas Medical Center, Kansas City, KS 66160, USA.
ORCID-Profile: Quan Zhang, Zhan Ye, X Long Zheng
Förderung
- NHLBI NIH HHS
- NHLBI
- Central South University, Changsha, China
Zitieren
APA
Zhang, Q., Ye, Z., Bignotti, A., & Zheng, X. L. (2023). Longitudinal Assessment of Plasma Syndecan-1 Predicts 60-Day Mortality in Patients with COVID-19. Journal of Clinical Medicine, 12(2), 552. https://doi.org/10.3390/jcm12020552
Vancouver
Zhang Q, Ye Z, Bignotti A, Zheng XL. Longitudinal Assessment of Plasma Syndecan-1 Predicts 60-Day Mortality in Patients with COVID-19. Journal of Clinical Medicine. 2023;12(2):552. doi:10.3390/jcm12020552
BibTeX
@article{Zhang2023,
author = {Zhang, Quan and Ye, Zhan and Bignotti, Antonia and Zheng, X Long},
title = {Longitudinal Assessment of Plasma Syndecan-1 Predicts 60-Day Mortality in Patients with COVID-19},
journal = {Journal of Clinical Medicine},
year = {2023},
volume = {12},
number = {2},
pages = {552},
doi = {10.3390/jcm12020552}
}
EUVIMED